
**Drug and Therapeutics Committees: Studies in
Australian hospitals**

Ee Lyn Tan

BPharm, BPharmSci (Hons)

**A thesis submitted in fulfilment of the requirements for the degree of
Doctor of Philosophy**



Faculty of Pharmacy

The University of Sydney

March 2005

Table of Contents

	PAGE
TABLE OF CONTENTS	2
STATEMENT OF ORIGINALITY	7
ACKNOWLEDGEMENTS	8
ABSTRACT	12
COMMUNICATIONS ARISING FROM THIS THESIS.....	15
LIST OF TABLES.....	18
LIST OF FIGURES	20
GLOSSARY OF ABBREVIATIONS	21
PREFACE.....	23
1. DRUG USE AND QUALITY USE OF MEDICINES	27
1.1 AUSTRALIA'S NATIONAL MEDICINES POLICY	30
1.1.1 <i>National policy on Quality Use of Medicines</i>	32
1.2 QUALITY IN HEALTH SERVICES.....	35
1.3 USE OF MEDICINES IN HOSPITALS.....	36
1.3.1 <i>Ensuring rational and evidence-based drug use in hospitals</i>	36
2. DRUG AND THERAPEUTICS COMMITTEES	38
2.1 INTRODUCTION.....	38
2.2 THE DEVELOPMENT OF DTCS	39
2.3 REPRESENTATION AND STRUCTURE	41
2.4 ROLES AND FUNCTION	44
2.5 QUALITY OF DTC PERFORMANCE.....	48
2.5.1 <i>Indicators as a tool for performance evaluation</i>	49
2.6 IMPLEMENTATION OF DTC DECISIONS	51
2.6.1 <i>Strategies used for policy implementation</i>	51
2.7 CONCLUSIONS	53

3.	EVALUATING AUSTRALIAN DTCs: A NATIONAL SURVEY.....	55
3.1	INTRODUCTION.....	55
3.2	AIMS.....	56
3.3	METHODS.....	56
3.3.1	<i>Pilot study</i>	59
3.3.2	<i>Data collection</i>	59
3.3.3	<i>Analysis and reporting</i>	60
3.4	RESULTS.....	62
3.4.1	<i>DTC functions</i>	65
3.4.1.1	Principal functions of DTCs.....	65
3.4.1.2	Extent to which current functions were achieved.....	66
3.4.1.3	Barriers to fully achieving principal functions.....	67
3.4.2	<i>DTC activities relating to performance evaluation</i>	68
3.4.2.1	Indicator use.....	68
3.4.2.2	Barriers to indicator use.....	70
3.4.2.3	Collectors of indicator data.....	70
3.4.3	<i>Resources available to DTCs</i>	71
3.4.4	<i>The extent of the DTCs' influence of prescribers' practices</i>	73
3.4.5	<i>Representation on DTCs</i>	74
3.5	DISCUSSION.....	77
4.	IMPLEMENTATION OF DTC DECISIONS AND POLICIES: A LOCAL AUDIT	83
4.1	INTRODUCTION.....	83
4.1.1	<i>Intervention strategies for policy implementation</i>	83
4.1.2	<i>Aims and objectives</i>	85
4.1.3	<i>Setting</i>	85
4.2	METHODS.....	86
4.2.1	<i>Pilot study</i>	86
4.2.2	<i>Data collection</i>	88
4.2.3	<i>Data analysis and reporting</i>	88
4.3	RESULTS.....	89
4.4	DISCUSSION.....	95
5.	PERSPECTIVES ON DTC POLICY IMPLEMENTATION: A QUALITATIVE STUDY	99
5.1	INTRODUCTION.....	99
5.1.1	<i>Study reference group</i>	99
5.1.2	<i>Organisational culture and change</i>	100
5.2	AIMS AND OBJECTIVES.....	101
5.3	METHODS.....	102
5.3.1	<i>Selection of methods</i>	102
5.3.1.1	Quantitative vs qualitative methods.....	102
5.3.1.2	Focus groups as a tool for qualitative research.....	105
5.3.2	<i>Participation in focus groups</i>	106
5.3.2.1	Selection of participants.....	106
5.3.2.2	Recruitment of participants.....	107
5.3.3	<i>Data collection & instrument development</i>	107

5.3.3.1	Focus group discussions	108
5.3.3.2	Demographic data	109
5.3.3.3	Transcription and thematic analysis	109
5.3.3.4	Reliability and validity	110
5.3.4	<i>Ethical considerations</i>	111
5.4	RESULTS	112
5.4.1	<i>Demographics</i>	112
5.4.2	<i>Themes</i>	114
5.4.2.1	Understanding of DTCs	114
5.4.2.1.1	DTC roles.....	115
5.4.2.1.2	Representation	116
5.4.2.2	Currently used intervention strategies	117
5.4.2.3	Application of intervention strategies	119
5.4.2.3.1	Targeted strategies	120
5.4.2.3.2	Timely implementation	121
5.4.2.3.3	Delivered at the point-of-care	121
5.4.2.3.4	Printed materials	122
5.4.2.3.5	Face-to-face strategies	123
5.4.2.3.6	Using existing forums within the organisation.....	124
5.4.2.4	Barriers to DTC policy implementation	125
5.4.2.4.1	Lack of resources	127
5.4.2.4.2	Lack of follow-up	128
5.4.2.4.3	Lack of ownership of DTC policies	130
5.4.2.4.4	Low DTC profile within its organisation.....	132
5.4.2.4.5	Relies on pharmacy for implementation	135
5.4.2.5	Ways to improve DTC policy implementation	138
5.4.2.5.1	Prioritise decisions	139
5.4.2.5.2	Optimise pharmacy roles	140
5.4.2.5.3	Give “real time” information	141
5.4.2.5.4	Seek organisational commitment.....	144
5.5	DISCUSSION.....	147

6. PRIORITISING DTC DECISIONS BASED ON “IMPORTANCE”: A NATIONAL SURVEY..... 153

6.1	INTRODUCTION.....	153
6.1.1	<i>Aims</i>	154
6.2	METHODS	154
6.2.1	<i>Questionnaire development</i>	154
6.2.1.1	Pilot study	155
6.2.2	<i>Data collection and analysis</i>	156
6.3	RESULTS	158
6.3.1	<i>Response rates</i>	158
6.3.2	<i>Demographics of respondents</i>	159
6.3.3	<i>Perceptions of domains (or criteria) of “important” decisions</i>	159
6.3.4	<i>Stakeholder opinions of “importance” and decision prioritisation</i>	160
6.3.5	<i>Stakeholder opinions about how DTC decisions could be prioritised</i>	162
6.4	DISCUSSION.....	164

7.	THE EFFECT OF LEVEL OF IMPORTANCE AND THE PRIMARY DOMAINS OF DTC DECISIONS ON PRIORITY ASSIGNMENT.....	168
7.1	INTRODUCTION.....	168
7.2	AIMS.....	169
7.3	METHODS.....	169
7.3.1	<i>Instrument development</i>	169
7.3.2	<i>Pilot study</i>	173
7.3.3	<i>Data collection</i>	174
7.3.3.1	Selection of participants.....	174
7.3.3.2	Analysis.....	175
7.3.3.3	Ethical considerations.....	176
7.4	RESULTS.....	177
7.4.1	<i>Respondent characteristics</i>	178
7.4.2	<i>Identification of primary domain</i>	182
7.4.3	<i>Stakeholders' perception of importance</i>	182
7.4.4	<i>Priority assignment</i>	183
7.4.5	<i>Relationship between level of importance and priority assignment</i> ...	184
7.4.6	<i>Impact of primary domains on perception of importance and priority assignment</i>	184
7.5	DISCUSSION.....	187
8.	SUMMARY AND FUTURE DIRECTIONS.....	194

APPENDICES

LIST OF APPENDICES.....	202
APPENDIX 3.1.....	203
QUESTIONNAIRE USED IN NATIONAL DTC SURVEY.....	203
APPENDIX 3.2.....	207
INVITATION TO PARTICIPATE IN DTC SURVEY.....	207
APPENDIX 4.1.....	208
DATA COLLECTION FORM USED IN REVIEW OF DTC MINUTES.....	208
APPENDIX 4.2.....	209
DETAILS OF ISSUES DISCUSSED AT DTC FROM JANUARY 2001 TO DECEMBER 2002.....	209
APPENDIX 5.1.....	232
INVITATION TO PARTICIPATE IN FOCUS GROUP DISCUSSIONS.....	232
APPENDIX 5.2.....	233
FOCUS GROUP REMINDER LETTER.....	233
APPENDIX 5.3.....	234

FOCUS GROUP REMINDER EMAIL.....	234
APPENDIX 5.4.....	235
FOCUS GROUP SCHEDULE	235
APPENDIX 5.5.....	238
DATA COLLECTION FORM (DEMOGRAPHIC DETAILS).....	238
APPENDIX 5.6.....	239
PARTICIPANT INFORMATION SHEET	239
APPENDIX 5.7.....	240
CONSENT FORM.....	240
APPENDIX 6.1.....	242
QUESTIONNAIRE USED IN NATIONAL SURVEY	242
APPENDIX 6.2.....	245
INVITATION TO PARTICIPATE IN SURVEY	245
APPENDIX 6.3.....	246
FOLLOW-UP LETTER FOR NON-RESPONDERS	246
APPENDIX 7.1.....	247
FORM USED IN PILOT STUDY TO COLLECT STAKEHOLDERS' OPINIONS ON HOW QUESTIONNAIRE COULD BE IMPROVED.....	247
APPENDIX 7.2.....	248
FINAL SURVEY QUESTIONNAIRE	248
APPENDIX 7.3.....	257
INVITATION TO PARTICIPATE IN SURVEY	257
APPENDIX 7.4.....	259
INTERACTIVE CD.....	259
APPENDIX 7.5.....	260
FOLLOW-UP REMINDER LETTER.....	260

BIBLIOGRAPHY	261
---------------------------	------------

Statement of originality

The research presented in this thesis was carried out under the supervision of **Prof Jo-anne Brien** (Chair of Clinical Pharmacy, The University of Sydney and St Vincent's Hospital) and **Prof Richard Day** (Director of the Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital).

To the best of my knowledge and belief, the work presented in this thesis is original; except as acknowledged in the text. Full acknowledgement has been made where the work of others have been cited or used. This thesis has not been submitted in part or in whole for the award of any other degree or diploma at any university or institution.

Ee Lyn Tan

March 2005

Acknowledgements

Although this thesis is mine, the credit for its successful completion is not mine alone. It has been both, a humbling and an enriching experience to have worked with many intelligent, dedicated, and inspiring people. I also owe much to those who have kept me balanced (and sane) throughout this journey.

The *American Heritage Dictionary* defined “mentor” as “a wise, and trusted counsellor or teacher”. I cannot find a better way to describe the role Professor Jo-anne Brien had played. Without Jo’s patience and guidance, none of this work would have been possible. It was Jo who introduced me to the wonders of research as an honours student, and subsequently encouraged me to pursue a career in research. I am grateful for the opportunities and experiences she has provided me with. These, and much more – I believe, will be valuable long after this thesis is completed.

I am also fortunate to have had the opportunity to have worked with Professor Richard Day. In spite of Ric’s immensely full schedule, he has always been approachable and helpful. I also appreciate the insight, knowledge and depth Ric has brought to this work. For his sense of humour, and support of my work, I am immensely grateful.

I am also indebted to Dr Sallie Pearson who, in the last few months, had given up huge chunks of her personal time to help me proof-read this thesis. I am amazed that she has so generously offered her time, because, in all honesty, she didn't have to. The suggestions she provided have helped to greatly improve the quality of this thesis.

I am grateful for the statistical advice of Judith Fethney (Research Centre for Adaptation of Health and Illness). I also thank Professor Charles Areni (School of Marketing, The University of Sydney) for patiently introducing me to qualitative research. I am also appreciative of the assistance provided by Neil Hardie (NSW Medicine Information Centre) for helping me track down literature which I would otherwise never be able to get my hands on. Thank you to Philip Lim (IT Department, National University of Singapore) for helping with the technicalities of the online survey. To the members of the reference group for this work – thank you for your availability.

Thank you also to Karen Kaye and the team at NSW TAG for always taking an interest in my work. The team at NSW TAG, Bill Thompson (VIC TAG), Sarah Venner & Bill Dollman (SA TAG), David Lyon (WA TAG), Di Aldous (Tasmanian Statewide DTC) and Andrew Petrie (Queensland Hospitals Statewide Drug Advisory Committee) have also been instrumental in helping us disseminate a national survey.

The drug committee at St Vincent's Hospital, particularly Professor Terry Campbell and Terry Melocco, inspired, and encouraged me with their enthusiasm and their

dedication to patients, and to the work of the DTC. I am also thankful for the support of the staff at the Pharmacy Department and the Department of Clinical Pharmacology & Toxicology at St Vincent's Hospital.

Thank you Clare, Gis and Sash - for helping me spot those typos. Thank you to the Clinical Pharmacy Research Group (especially Sasha, Gisselle, Meredith, David, Ayman) and other fellow-researchers at the Therapeutics Centre (especially Christine and Clare) without whom, these would have been unbearably lonely years. Thank you for the delightful friendships.

My colleagues (particularly Sreeja, Elaine, Tam and Johnson) at the Victorian College of Pharmacy, Monash University – I am grateful to have their support, friendship and encouragement. Thank you for listening to me whinge when things just did not seem to be going right.

It would not have been possible for me to conduct this research without the financial support of the Commonwealth Department of Education, Training and Youth Affairs through the Australian Postgraduate Award. The Society of Hospital Pharmacists of Australia had also funded various studies within this research through the DBL Development Fund (DBL01009 & DBL02018). I would like to acknowledge their support of this work.

On a personal note, an acquaintance recently commented that I must be looking forward to “having my life back” after I hand in this thesis. As I pondered upon that comment, I am grateful to say that the last 3+ years have been a pretty balanced

journey. For this, I would like to give credit to my “fun-&-food-loving” group of ex-high school friends (especially Eunice and Shu), and also to my awesome “family” at Hillsong Church (especially John and Clara). I also treasure those in my other social networks who have been significant in making sure I still “had a life”.

Words are inadequate to express my gratitude to my family for their exceptional dedication to my dreams. Mum and Dad – thanks for always having my best interest at heart, and for always enthusiastically supporting my academic pursuits. This is LAST degree....I promise!!! To my husband, Justin - thank you for your love, emotional support and level-headed influence on my life. Your prayers have been an anchor in times of turbulence and uncertainty.

Finally, and most importantly, I am grateful to my Lord and friend – whose abounding *love, grace* and *peace* truly surpasses ALL understanding.

I have been exceedingly blessed.

Abstract

Australia's policy on Quality Use of Medicines (QUM) aims to achieve appropriate use of medicines and improved health outcomes. Drug and Therapeutics Committees (DTCs) are educators, policy makers as well as financial gatekeepers in matters relating to medicine use. Increasingly, DTCs are also involved in risk management and clinical governance. As such, DTCs could be considered to be QUM advocates in the institutions in which they function. In a health care arena where there are escalating demands on high standards of clinical practice, quality assessment and improvement is essential in ensuring safe and effective patient care. Given the role DTCs play in safeguarding the interests of the stakeholders of the health care system, research into ways in which DTC performance could be enhanced is required.

Although indicators specific to DTCs exist, the literature does not seem to provide straightforward answers to the question of what is currently being done in terms of quality assessment and quality improvement of DTCs. In the absence of such data, an opportunity for research is clearly identified. The first aim of this research project was to gain insight into the current activities undertaken by, and challenges facing Australian DTCs. Following this, the second aim was to explore ways in which DTC performance could be augmented.

In addressing the first aim of this project, a national survey of Australian DTCs was conducted. These findings reinforce the evidence in the literature about the roles,

structure and stakeholder expectations of DTCs. Our research also documents DTCs' quality improvement initiatives and barriers to DTC activities. It appears that there is little support available to Australian DTCs. Further, a case study was undertaken in order to gain an understanding of the depth and detail of DTC operations. An audit of a DTC in an Australian hospital was conducted. This study revealed that DTC decisions are being implemented in an *ad hoc* manner. In fact, there were no strategies (or action) planned to implement the majority of their decisions. This could have an impact on DTC performance.

In view of this finding, qualitative methods were used to explore stakeholder opinions regarding the implementation of DTC decisions and policies. Stakeholders believed that strategies used to implement DTC policies should be targeted (to the audience as well as the type of decision/policy being implemented), timely, and delivered at the point of care. Face-to-face strategies were perceived to be more effective than printed materials, particularly when an influence on clinical practice was desired. Stakeholders also felt that the lack of resources was a significant barrier to DTC performance augmentation. This probably contributed to a lack of follow-up (or review) of implemented policies. According to stakeholders, other barriers to policy implementation include a lack of ownership of policies, low DTC profile, and an over-reliance on pharmacy to implement DTC decisions. Stakeholders felt one of the ways in which DTC performance could be improved was to prioritise DTC decisions for implementation.

In pursuit of a method to prioritise DTC decisions, a survey was conducted. Stakeholders identified patient safety, cost, and the practice of evidence-based medicine as domains of important DTC decisions. The results also suggest that

stakeholders recognise the need for the prioritisation of DTC decisions for implementation. Stakeholders implied that higher priority would be assigned to DTC decisions considered to be important. In a follow-up survey, stakeholders (including doctors, nurses, pharmacists, and DTC members) seemed to have agreement of the primary domains of DTC decisions. Higher levels of importance and higher priority were assigned to decisions involving the primary domains of patient safety and cost. However, level of importance and priority assignment were not consistently correlated.

The work presented in this thesis suggests that there are ways to improve DTC performance. Although conducted primarily on hospital-based DTCs, it is anticipated that the lessons learnt could be applied to state-based, or even, Area Health-based DTCs. In conclusion, this research found that there was a range of views regarding “importance” and prioritisation for implementation. Social, organisational, as well as environmental factors may contribute to this. Future research should examine other possible factors contributing to the importance and priority of DTC decisions, so that DTC policy could be appropriately implemented into practice.

Communications arising from this thesis

The work described in this thesis has been presented as follows:

PEER REVIEWED PUBLICATIONS

- 2003 Tan EL, Day RO, Brien JE. Improving decision outcomes of Drug and Therapeutics Committees. *J Pharm Pract Res* 2003; 33:65-7
- 2003 Tan EL, Day RO, Brien JE. Drugs and Therapeutics Committees – Potential to improve the Quality Use of Medicines. *Int J Pharm Pract* 2003; 11:175-81
- 2004 Tan EL, Day RO, Brien JE. Stakeholder opinions on the implementation of Drug and Therapeutics Committee decisions. *J Pharm Pract Res* 2004; 34:178-82
- 2005 Tan EL, Day RO, Brien JE. Perspectives on Drug and Therapeutics Committee (DTC) policy implementation. *Res Soc Adm Pharm* (in press)

PUBLISHED ABSTRACTS

- 2004 Tan EL, Day RO, Brien JE. Stakeholder opinions of Drug and Therapeutics Committee (DTC) policy implementation strategies. *Clin Exp Pharmacol Physiol* 2004; 31(Suppl 1):A83-A84

SCIENTIFIC PRESENTATIONS – Australasian Conferences

- 2001 Tan EL, Day RO, Melocco T, Brien JE. How to assess outcomes of Drug and Therapeutics Committees. Federal Conference of the Society of Hospital Pharmacists of Australia. Hobart
- 2001 Tan EL, Day RO, Brien JE. Drug and Therapeutics Committee (DTC) performance evaluation. Australian Pharmaceutical Sciences Association Conference. Melbourne
- 2002 Tan EL, Day RO, Brien JE. Use of performance indicators for Drug and Therapeutics Committees. National Medicines Symposium. Canberra
- 2002 Tan EL, Day RO, Brien JE. QUM and the Drug Committee: Current principle functions of DTCs. Society of Hospital Pharmacists of Australia (NSW Branch) Conference. Leura
- 2002 Tan EL, Day RO, Brien JE. Implementation of DTC decisions: Implementation to improve prescribing. Australasian Pharmaceutical Sciences Association Conference. Melbourne
- 2003 Tan EL, Day RO, Brien JE. From policy to practice: Improving the effectiveness of DTC decision implementation. Federal Conference of the Society of Hospital Pharmacists of Australia. Canberra
- 2004 Tan EL, Day RO, Brien JE. Barriers to Drug and Therapeutics Committee (DTC) policy implementation. National Medicines Symposium. Brisbane
- 2004 Tan EL, Day RO, Brien JE. What makes a decision of a Drug and Therapeutics Committee (DTC) “important”? Australasian Pharmaceutical Sciences Association Conference. Melbourne
- 2004 Tan EL, Day RO, Brien JE. Strategies to implement Drug and Therapeutics Committee (DTC) decisions. 4th College of Health Sciences Research Conference (The University of Sydney). Leura

SCIENTIFIC PRESENTATIONS – International Conferences

- 2002 Tan EL, Day RO, Brien JE. Current principal functions of Drug and Therapeutics Committees. International Social Pharmacy Workshop (ISPW). Sydney (Australia)
- 2003 Tan EL, Day RO, Campbell TJ, Melocco T, Brien JE. DTC decision implementation: Experience at a teaching hospital. 63rd World Congress of the International Pharmaceutical Federation (FIP). Sydney (Australia)*
- 2004 Tan EL, Day RO, Brien JE. Stakeholder opinions of Drug and Therapeutics Committee (DTC) policy implementation strategies. 8th World Conference on Clinical Pharmacology and Therapeutics (Incorporating the Annual Scientific Meeting of ASCEPT). Sydney (Australia)
- 2004 Tan EL, Day RO, Brien JE. A qualitative investigation of Drug and Therapeutics Committee (DTC) policy implementation. 33rd European Symposium on Clinical Pharmacy (ESCP). Prague (Czech Republic)

* Best presentation – Hospital Pharmacy Section

List of tables

	Page
Chapter 3	
3.1	Details of data collected in questionnaire 58
3.2	Categories of hospitals involved in the survey (as defined by the Australian Institute of Health and Welfare) 64
3.3	Reasons for collecting indicator data 69
3.4	Collectors of indicator data 71
3.5	Representatives on DTCs 75
3.6	Specialist units represented on DTCs 76
Chapter 4	
4.1	Number of issues and the number of strategies planned per issue 90
4.2	Total number of strategies planned by DTC 91
Chapter 5	
5.1	Traditional characteristics of qualitative and quantitative research approaches 105
5.2	Focus group participant demographics 113
5.3	Summary of themes (Understanding of DTCs) 114
5.4	Summary of themes (Application of intervention strategies) 120
5.5	Summary of themes (Barriers to DTC policy implementation) 126

5.6	Summary of themes (Ways to improve DTC policy implementation)	138
-----	---	-----

Chapter 6

6.1	Data collected in questionnaire	155
6.2	Characteristics of respondents	159
6.3	Respondents' opinions about the prioritisation of DTC decisions	160
6.4	Importance-urgency grid (suggested by respondent)	163

Chapter 7

7.1	Characteristics of respondents	179
7.2	Summary of results for DTC decisions described in each scenario	181
7.3	Summary of results according to primary domains identified	185

List of figures

	Page
Chapter 1	
1.1	Australia's National Medicines Policy 34
Chapter 3	
3.1	Selection of final dataset 62
3.2	Extent to which DTCs were achieving their principal functions 67
3.3	Extent of DTCs' influence on prescribers' practices 73
Chapter 4	
4.1	Number of intervention strategies planned and undertaken 92
Chapter 6	
6.1	Selection of responses for analysis 158
Chapter 7	
7.1	Hypothetical DTC described in questionnaire 170
7.2	Scenarios developed for questionnaire 171
7.3	Selection of final dataset 177

Glossary of abbreviations

χ^2	chi-squared test
ABS	Australian Bureau of Statistics
ACHS	Australian Council on Healthcare Standards
ACSQHC	Australian Council on Safety & Quality in Health Care
ADEC	Australian Drug Evaluation Committee
ADR	Adverse Drug Reaction
ADRAC	Australian Drug Reactions Advisory Committee
AIHW	Australian Institute of Health and Welfare
APAC	Australian Pharmaceutical Advisory Council
APSF	Australian Patient Safety Foundation
ASHP	American Society of Hospital (now, Health-System) Pharmacists
AUD	Australian Dollars
CAP	community acquired pneumonia
CE	continuing education
CI	confidence interval
CMEC	Complementary Medications Evaluation Committee
DTC	Drug and Therapeutics Committees
DUE	drug usage evaluation
EBM	evidence-based medicine
EPOC	Effective Practice and Organization of Care group
GP(s)	General practitioner(s)
HREC	Human Research and Ethics Committee
IP address	Internet Protocol address
IV	intravenous
JCAHO	Joint Commission on Accreditation of Healthcare Organisations
MEC	Medication Evaluation Committee
NICS	National Institute of Clinical Studies
NMP	National Medicines Policy
NPS	National Prescribing Service
NSW	New South Wales
NSW ICE	New South Wales Institute for Clinical Excellence
NSW TAG	New South Wales Therapeutic Assessment (now Advisory) Group
OTC	Over-the-Counter

P&TC	Pharmacy and Therapeutics Committees
PBS	Pharmaceutical Benefits Scheme
PCP(s)	primary care physician(s)
PHARM	Pharmaceutical Health and Rational Use of Medicines
QI	quality improvement
QUM	Quality Use of Medicines
<i>r</i>	Spearman's rho (for ordinal data)
RACGP	Royal Australia College of General Practice
SA TAG	South Australian Therapeutic Advisory Group
SAC	severity assessment code
SHPA	Society of Hospital Pharmacists of Australia
SPSS	Statistical Package for the Social Sciences
SVH	St Vincent's Hospital, Sydney
TGA	Therapeutic Goods Administration
UK	United Kingdom
USA, US	United States of America
USD	American Dollars
VDUAC	Victorian Drug Usage Advisory Committee – subsequently VIC TAG
VIC TAG	Victorian Therapeutic Advisory Group
WA TAG	Western Australian Therapeutic Advisory Group
WHO	World Health Organisation

Preface

The work set out in this thesis investigates the little researched area of Drug and Therapeutics Committees (DTCs) within the Australian health care setting. Health care is concerned with ensuring the safe and efficacious use of medications to treat diseases and maintain health. The Australian health care system is considered to be among the best in the world.(1) One of the reasons for this may be because Australia has a national medicines policy on quality use of medicines.

DTC decisions may influence the types, ways, and amount of medications used in hospitals. DTCs play a pivotal role in ensuring value-for-money use of medicines within their institutions. Therefore, it could be argued that DTCs contribute to achieving rational drug use in their institutions.

Evidence based medicine has become an accepted paradigm for clinical decision making.(2, 3) DTCs frequently develop guidelines and policies regarding the use of medicines, based on evidence.(4) However, evidence-based guidelines and policies can be undermined if they are disregarded by practitioners and clinicians because of inconsistent, inappropriate and ineffective implementation. Evidence-based decisions need to be followed by evidence-based implementation. *Ad hoc* implementation could also contribute to a considerable gap between knowledge and practice. If DTCs are to contribute successfully to achieving quality use of medicines, then more needs to be done to ensure that the investment of time, expertise, effort and knowledge on DTC decisions is not wasted.

This research examines the current challenges facing drug committees in Australia and the ways in which DTC outcomes and performance could be improved. It is surprising to note that despite the importance of quality use of medicines for health outcomes in hospitals, little work has been conducted in this area of research previously.

This thesis is divided into three broad sections. In the first section, Chapters 1 and 2, a literature review is presented. A review of drug use is presented in Chapter 1. This includes an overview of the extent of drug use, problems relating to drug use, the need for quality in drug use as well as drug use in hospitals. The principles of quality use of medicines (QUM) are also outlined in Chapter 1. This review underpins the subsequent research in this thesis. In Chapter 2, a review of the literature is presented. The published literature relating to DTCs was reviewed with the purpose of understanding the representation, structure, roles and function of DTCs.

The second section, Chapters 3 and 4, describes two evaluations of DTCs in Australia. Chapter 3 reports a national survey of DTCs. This work adds to the current “macro-view” of Australian DTCs. This study also explores functions, representation, resources (how are Australian DTCs being supported), and performance (performance evaluation including influence on prescribing as determined by the DTCs). Chapter 4 presents a “micro-view” of a DTC in an Australian hospital. In this chapter, an audit of the DTC’s decisions was conducted in order to investigate how decisions were being implemented.

The third section of this thesis, (Chapters 5 to 7) includes three studies. These studies explored strategies to improve DTC performance. Qualitative and quantitative methodologies were employed. A consistent theme from the results (in Chapters 3, 4 and 5) was that DTCs were functioning with scarce resources. This lack of resource has significant consequences on the implementation and follow-up of DTC decisions. A novel approach to decision implementation needed to be explored. However, there is an absence of information in the public domain as to what could be done.

In light of this, the prioritisation of DTC decisions for implementation was explored. This is described in the last section of the thesis. A chosen approach (based on the findings in Chapter 5) was to assign higher priority to those decisions which were considered more important. Chapter 6 details a survey of stakeholders undertaken to identify what were the criteria (or domains) used to determine important decisions. In Chapter 7, priority setting based on these “criteria of importance” was explored. Stakeholders’ identification of the primary criteria (or domains) relating to DTC decisions was investigated. In this study, stakeholders’ assignment of priority to decisions which they considered important was also examined.

The final chapter (Chapter 8) summarises major findings and draws some general conclusions and implications of this work.

Currently, DTCs function in an environment where much is expected of them, yet little is invested in them. It appears decisions are implemented, at best, in a

piecemeal fashion. The results of this work raise important issues concerning the ways in which DTCs function, as unimplemented decisions may diminish the possibility for quality use of medicines.